Prolonged converting enzyme inhibition in non-modulating hypertension.

Anti-ischemic effects of angiotensin- converting enzyme inhibition in hypertension.

OBJECTIVES We investigated whether augmentation of bradykinin (BK) bioavailability with angiotensin-converting enzyme (ACE) inhibition is associated with reduced exercise-induced myocardial ischemia in hypertension. BACKGROUND Bradykinin responses are depressed in hypertension, and endothelial dysfunction contributes to myocardial ischemia by promoting abnormal coronary vasomotion during stre...

Angiotensin Converting Enzyme in Sarcoidosis

Oral converting enzyme inhibitor in malignant hypertension.

Malignant hypertension, which developed in a 9-year-old boy after an episode of haemolytic uraemic syndrome, could not be controlled with antihypertensive agents. However, treatment with oral converting enzyme inhibitor (captopril) was effective in controlling the blood pressure and it averted bilateral nephrectomy. No adverse effects from the drug were noted.

Non-modulating Hypertension

Patients with normalor high-renin non-modulating essential hypertension fail to shift their adrenal sensitivity on a low sodium diet in response to an infusion of angiotensin II (Ang II). In a prior study, 72 hours of converting enzyme inhibition (CEI) partially corrected this subnormal aldosterone response to Ang II hi patients with non-modulating hypertension. Since it was uncertain whether t...

Angiotensin converting enzyme inhibitors and pulmonary hypertension.

AIM To evaluate the efficacy of angiotensin converting enzyme inhibitors Enalapril, Fosonopril and Moexipril on mean and systolic pulmonary artery pressure. MATERIAL AND METHODS The study included Ill patients with chronic obstructive bronchopneumopathies associated with arterial hypertension and mild to moderate heart failure (NYHA I-II class). The patients were examined at baseline and afte...